CoChat

Pharmacokinetics and pharmacodynamics of nasally delivered midazolam

Open access
Haschke, Manuel, Suter, Katja, Hofmann, Sarah, Witschi, Robert, Fröhlich, Johannes, Imanidis, Georgios, Drewe, Jürgen, Briellmann, Thomas A., Dussy, Franz E., Krähenbühl, Stephan, Surber, Christian · 2010 · British Journal of Clinical Pharmacology
Cited by 56

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Nasal application of midazolam has been studied for a variety of indications. Due to the limited application volume, highly concentrated formulations are required to reach clinically relevant concentrations in adult patients. No data on the pharmacokinetics and pharmacodynamics of nasal midazolam formulations based on cyclodextrin and chitosan are available. WHAT THIS STUDY ADDS • Clinically effective midazolam concentrations can be reached within less than 10 min after nasal administration of highly concentrated formulations containing an equimolar amount of the solubilizer randomly methylated‐β‐cyclodextrin combined with the absorption enhancer chitosan. Immediate non‐invasive application of such formulations in emergency treatment of seizure patients by lay persons could offer clinical benefits in situations where intravenous access cannot be quickly established. AIMS To investigate the pharmacokinetics and pharmacodynamics of nasal formulations containing midazolam (5–30 mg ml−1) complexed with cyclodextrin. METHODS An open‐label sequential trial was conducted in eight healthy subjects receiving single doses of 1 mg and 3 mg intranasally and 1 mg midazolam intravenously. Pharmacokinetic parameters were obtained by non‐compartmental and two‐compartmental models. Pharmacodynamic effects of midazolam were assessed using VAS and a reaction time test. RESULTS Mean bioavailability of midazolam after nasal administration ranged from 76 ± 12% to 92 ± 15%. With formulations delivering 1 mg midazolam, mean Cmax values between 28.1 ± 9.1 and 30.1 ± 6.6 ng ml−1 were reached after 9.4 ± 3.2–11.3 ± 4.4 min. With formulations delivering 3 mg midazolam, mean Cmax values were between 68.9 ± 19.8 and 80.6 ± 15.2 ng ml−1 after 7.2 ± 0.7–13.0 ± 4.3 min. Chitosan significantly increased Cmax and reduced tmax of midazolam in the high‐dose formulation. Mean ratios of dose‐adjusted AUC after intranasal and intravenous application for 1′‐hydroxymidazolam were between 0.97 ± 0.15 and 1.06 ± 0.24, excluding relevant gastrointestinal absorption of intranasal midazolam. The pharmacodynamic effects after the low‐dose nasal formulations were comparable with those after 1 mg intravenous midazolam. The maximum increase in reaction time by the chitosan‐containing formulation delivering 3 mg midazolam was greater compared with 1 mg midazolam i.v. (95 ± 78 ms and 19 ± 22 ms, mean difference 75.5 ms, 95% CI 15.5, 135.5, P < 0.01). Intranasal midazolam was well tolerated but caused reversible irritation of the nasal mucosa. CONCLUSIONS Effective midazolam serum concentrations were reached within less than 10 min after nasal application of a highly concentrated midazolam formulation containing an equimolar amount of the solubilizer RMβCD combined with the absorption enhancer chitosan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2010.03611.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 56

Metadata

Authors
Haschke, M., Suter, K., Hofmann, S., Witschi, R., Fröhlich, J., Imanidis, G., Drewe, J., Briellmann, T. A., Dussy, F. E., Krähenbühl, S., & Surber, C.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2010-05-10
Volume
69
Issue
6
Pages
607-616
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2101445492
Cited by
56
References
3
FWCI
2.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. https://app.cochat.ai/papers/10.1111/j.1365-2125.2010.03611.x
The paper
Haschke, M., Suter, K., Hofmann, S., Witschi, R., Fröhlich, J., Imanidis, G., Drewe, J., Briellmann, T. A., Dussy, F. E., Krähenbühl, S., & Surber, C. (2010). Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2010.03611.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.